Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization

References

• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• UzaslanEMahboubBBejiMThe burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE studyRespir Med2012106S45S5923290704
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• MullerovaHMaselliDJLocantoreNHospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohortChest20151474999100725356881
   PubMed Web of Science ®Google Scholar
• BahadoriKFitzGeraldJMRisk factors of hospitalization and readmission of patients with COPD exacerbation – systematic reviewInt J Chron Obstruct Pulmon Dis20072324125118229562
   PubMedGoogle Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
   PubMed Web of Science ®Google Scholar
• HurstJRDonaldsonGCPereraWRUse of plasma biomarkers at exacerbation of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2006174886787416799074
   PubMed Web of Science ®Google Scholar
• BozinovskiSHutchinsonAThompsonMSerum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177326927818006888
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTAPatelISAirway and systemic inflammation and decline in lung function in patients with COPDChest200512841995200416236847
   PubMed Web of Science ®Google Scholar
• PrasseAPechkovskyDVToewsGBCCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosisArthritis Rheum20075651685169317469163
   PubMed Web of Science ®Google Scholar
• SinDDMillerBEDuvoixASerum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201118391187119221216880
   PubMed Web of Science ®Google Scholar
• Pinto-PlataVCasanovaCMüllerovaHInflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPDRespir Res20121317122906131
   PubMed Web of Science ®Google Scholar
• BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J2003414653
   Web of Science ®Google Scholar
• CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• DonaldsonGCMüllerovaHLocantoreNFactors associated with change in exacerbation frequency in COPDRespir Res2013147923899210
   PubMed Web of Science ®Google Scholar
• BestallJPaulEGarrodRGarnhamRJonesPWedzichaJUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax199954758158610377201
   PubMed Web of Science ®Google Scholar
• JonesPHardingGBerryPWiklundIChenWLeidyNKDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• YorgancıoğluAPolatlıMAydemirÖReliability and validity of Turkish version of COPD assessment testTuberk Toraks2011604314320 Turkish
   Google Scholar
• MillerMRCrapoRHankinsonJGeneral considerations for lung function testingEur Respir J200526115316115994402
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function LaboratoriesATS statement: guidelines for the six-minute walk testAm J Respir Crit Care Med2002166111112091180
   PubMed Web of Science ®Google Scholar
• CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350101005101214999112
   PubMed Web of Science ®Google Scholar
• CharlsonMSzatrowskiTPPetersonJGoldJValidation of a combined comorbidity indexJ Clin Med1994471112451251
   Google Scholar
• NicholasBLSearch for biomarkers in chronic obstructive pulmonary disease: current statusCurr Opin Pulm Med201319210310823361193
   PubMed Web of Science ®Google Scholar
• SchutyserERichmondAVan DammeJInvolvement of CC chemokine ligand 18 (CCL18) in normal and pathological processesJ Leukoc Biol2005781142615784687
   PubMed Web of Science ®Google Scholar
• KoderaMHasegawaMKomuraKYanabaKTakeharaKSatoSSerum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosisArthritis Rheum20055292889289616142750
   PubMed Web of Science ®Google Scholar
• PrasseAPechkovskyDVToewsGBA vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18Am J Respir Crit Care Med2006173778179216415274
   PubMed Web of Science ®Google Scholar
• BoorsmaCEDraijerCMelgertBNMacrophage heterogeneity in respiratory diseasesMediators inflamm2013201376921423533311
   PubMed Web of Science ®Google Scholar
• SchraufstatterIUZhaoMKhaldoyanidiSKDiScipioRGThe chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrumImmunology2012135428729822117697
   PubMed Web of Science ®Google Scholar
• StahlMSchuppJJägerBLung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activationPLoS One2013811e8138224278429
   PubMed Web of Science ®Google Scholar
• DoyleTJPinto-PlataVMorseDCelliBRRosasIOThe expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseasesChest201214241027103423032451
   PubMed Web of Science ®Google Scholar
• ShaykhievRKrauseASalitJSmoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary diseaseJ Immunol200918342867288319635926
   PubMed Web of Science ®Google Scholar
• MurrayLAHogaboamCMMechanisms promoting chronic lung diseases: will targeting stromal cells cure COPD and IPF?IrusenEMLung Diseases – Selected State of the Art ReviewsInTech2012 Available from: http://www.intechopen.com/books/lung-diseases-selected-state-of-the-art-reviews/mechanisms-promoting-chronic-lung-diseases-will-targeting-stromal-cells-cure-copd-and-ipf-Accessed July 29, 2016
   Google Scholar
• BeehKMGlaabTStowasserSCharacterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialRespir Res20131411624168767
   PubMed Web of Science ®Google Scholar
• MackayAJDonaldsonGCPatelARJonesPWHurstJRWedzichaJAUsefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbationsAm J Respir Crit Care Med2012185111218122422281834
   PubMed Web of Science ®Google Scholar
• LeeSJLeeSHKimYEClinical features according to the frequency of acute exacerbation in COPDTuberc Respir Dis (Seoul)201272436737323227078
   PubMedGoogle Scholar
• Al AhmariADPatelAKowlessarBCOPD exacerbation frequency phenotype and exercise capacityAm J Respir Crit Care Med2013187A1440
   Web of Science ®Google Scholar
• MarinJMCarrizoSJCasanovaCPrediction of risk of COPD exacerbations by the BODE indexRespir Med2009103337337819013781
   PubMed Web of Science ®Google Scholar
• KollertFProbstCMüller-QuernheimJZisselGPrasseACCL18 production is decreased in alveolar macrophages from cigarette smokersInflammation200932316316819357939
   PubMed Web of Science ®Google Scholar
• GroenewegenKHPostmaDSHopWCWieldersPLSchlosserNJWoutersEFIncreased systemic inflammation is a risk factor for COPD exacerbationsChest2008133235035718198263
   PubMed Web of Science ®Google Scholar